Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors

Abstract excerpt

Background/Objectives: Cutaneous side effects are the most common immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) and affect 70–90% of patients. Besides diverse types of exanthema, rare skin toxicity includes bullous dermatoses in 0.3% of cases. Systemic steroids are the first-line treatment for immune-related bullous pemphigoid (irBP); however, some cases are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autoimmune Bullous Skin Diseases
• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to Urticaria and Related Conditions